Anavex Life Sciences Past Earnings Performance
Past criteria checks 0/6
Anavex Life Sciences's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-14.4%
Earnings growth rate
-3.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -32.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Anavex Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -42 | 11 | 38 |
| 31 Mar 24 | 0 | -41 | 11 | 36 |
| 31 Dec 23 | 0 | -43 | 11 | 38 |
| 30 Sep 23 | 0 | -48 | 12 | 41 |
| 30 Jun 23 | 0 | -52 | 13 | 42 |
| 31 Mar 23 | 0 | -53 | 13 | 41 |
| 31 Dec 22 | 0 | -50 | 13 | 38 |
| 30 Sep 22 | 0 | -48 | 13 | 35 |
| 30 Jun 22 | 0 | -45 | 12 | 32 |
| 31 Mar 22 | 0 | -43 | 11 | 32 |
| 31 Dec 21 | 0 | -41 | 11 | 29 |
| 30 Sep 21 | 0 | -38 | 9 | 28 |
| 30 Jun 21 | 0 | -32 | 8 | 24 |
| 31 Mar 21 | 0 | -28 | 7 | 22 |
| 31 Dec 20 | 0 | -28 | 6 | 22 |
| 30 Sep 20 | 0 | -26 | 6 | 21 |
| 30 Jun 20 | 0 | -26 | 6 | 20 |
| 31 Mar 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -26 | 7 | 20 |
| 30 Sep 19 | 0 | -26 | 7 | 20 |
| 30 Jun 19 | 0 | -26 | 7 | 20 |
| 31 Mar 19 | 0 | -23 | 7 | 16 |
| 31 Dec 18 | 0 | -20 | 7 | 14 |
| 30 Sep 18 | 0 | -17 | 6 | 11 |
| 30 Jun 18 | 0 | -17 | 6 | 11 |
| 31 Mar 18 | 0 | -18 | 6 | 12 |
| 31 Dec 17 | 0 | -14 | 5 | 9 |
| 30 Sep 17 | 0 | -13 | 5 | 9 |
| 30 Jun 17 | 0 | -15 | 7 | 8 |
| 31 Mar 17 | 0 | -13 | 7 | 7 |
| 31 Dec 16 | 0 | -14 | 6 | 8 |
| 30 Sep 16 | 0 | -15 | 8 | 7 |
| 30 Jun 16 | 0 | -14 | 8 | 4 |
| 31 Mar 16 | 0 | -16 | 8 | 4 |
| 31 Dec 15 | 0 | -15 | 8 | 3 |
| 30 Sep 15 | 0 | -12 | 5 | 2 |
| 30 Jun 15 | 0 | -15 | 2 | 2 |
| 31 Mar 15 | 0 | -12 | 2 | 1 |
| 31 Dec 14 | 0 | -11 | 2 | 1 |
| 30 Sep 14 | 0 | -10 | 2 | 1 |
| 30 Jun 14 | 0 | -5 | 3 | 0 |
| 31 Mar 14 | 0 | -4 | 3 | 0 |
Quality Earnings: AVXL is currently unprofitable.
Growing Profit Margin: AVXL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVXL is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare AVXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AVXL has a negative Return on Equity (-32%), as it is currently unprofitable.